KW-2449
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia (AML)
Conditions
Acute Myelogenous Leukemia (AML)
Trial Timeline
Jan 1, 2009 → Dec 1, 2010
NCT ID
NCT00779480About KW-2449
KW-2449 is a phase 1 stage product being developed by Kyowa Kirin for Acute Myelogenous Leukemia (AML). The current trial status is terminated. This product is registered under clinical trial identifier NCT00779480. Target conditions include Acute Myelogenous Leukemia (AML).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00779480 | Phase 1 | Terminated |
| NCT00346632 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myelogenous Leukemia (AML)